197 related articles for article (PubMed ID: 24401613)
1. A novel vascular homing peptide strategy to selectively enhance pulmonary drug efficacy in pulmonary arterial hypertension.
Toba M; Alzoubi A; O'Neill K; Abe K; Urakami T; Komatsu M; Alvarez D; Järvinen TA; Mann D; Ruoslahti E; McMurtry IF; Oka M
Am J Pathol; 2014 Feb; 184(2):369-75. PubMed ID: 24401613
[TBL] [Abstract][Full Text] [Related]
2. Peptide-directed highly selective targeting of pulmonary arterial hypertension.
Urakami T; Järvinen TA; Toba M; Sawada J; Ambalavanan N; Mann D; McMurtry I; Oka M; Ruoslahti E; Komatsu M
Am J Pathol; 2011 Jun; 178(6):2489-95. PubMed ID: 21549345
[TBL] [Abstract][Full Text] [Related]
3. Imatinib attenuates monocrotaline pulmonary hypertension and has potent vasodilator activity in pulmonary and systemic vascular beds in the rat.
Pankey EA; Thammasiboon S; Lasker GF; Baber S; Lasky JA; Kadowitz PJ
Am J Physiol Heart Circ Physiol; 2013 Nov; 305(9):H1288-96. PubMed ID: 23997103
[TBL] [Abstract][Full Text] [Related]
4. CAR, a Homing Peptide, Prolongs Pulmonary Preferential Vasodilation by Increasing Pulmonary Retention and Reducing Systemic Absorption of Liposomal Fasudil.
Keshavarz A; Alobaida A; McMurtry IF; Nozik-Grayck E; Stenmark KR; Ahsan F
Mol Pharm; 2019 Aug; 16(8):3414-3429. PubMed ID: 31194563
[TBL] [Abstract][Full Text] [Related]
5. Fasudil and DETA NONOate, Loaded in a Peptide-Modified Liposomal Carrier, Slow PAH Progression upon Pulmonary Delivery.
Rashid J; Nahar K; Raut S; Keshavarz A; Ahsan F
Mol Pharm; 2018 May; 15(5):1755-1765. PubMed ID: 29528655
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats.
Abe K; Toba M; Alzoubi A; Koubsky K; Ito M; Ota H; Gairhe S; Gerthoffer WT; Fagan KA; McMurtry IF; Oka M
Am J Respir Cell Mol Biol; 2011 Oct; 45(4):804-8. PubMed ID: 21378262
[TBL] [Abstract][Full Text] [Related]
7. Peptide-micelle hybrids containing fasudil for targeted delivery to the pulmonary arteries and arterioles to treat pulmonary arterial hypertension.
Gupta N; Ibrahim HM; Ahsan F
J Pharm Sci; 2014 Nov; 103(11):3743-3753. PubMed ID: 25266507
[TBL] [Abstract][Full Text] [Related]
8. An evidence-based approach to the management of pulmonary arterial hypertension.
Archer SL; Michelakis ED
Curr Opin Cardiol; 2006 Jul; 21(4):385-92. PubMed ID: 16755209
[TBL] [Abstract][Full Text] [Related]
9. Cocktail of Superoxide Dismutase and Fasudil Encapsulated in Targeted Liposomes Slows PAH Progression at a Reduced Dosing Frequency.
Gupta N; Rashid J; Nozik-Grayck E; McMurtry IF; Stenmark KR; Ahsan F
Mol Pharm; 2017 Mar; 14(3):830-841. PubMed ID: 28165252
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of the susceptibility of remodeled pulmonary vessels to drug-induced cell killing.
Ibrahim YF; Wong CM; Pavlickova L; Liu L; Trasar L; Bansal G; Suzuki YJ
J Am Heart Assoc; 2014 Feb; 3(1):e000520. PubMed ID: 24572252
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.
Michelakis ED; Tymchak W; Noga M; Webster L; Wu XC; Lien D; Wang SH; Modry D; Archer SL
Circulation; 2003 Oct; 108(17):2066-9. PubMed ID: 14568893
[TBL] [Abstract][Full Text] [Related]
12. Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression.
Ciuclan L; Hussey MJ; Burton V; Good R; Duggan N; Beach S; Jones P; Fox R; Clay I; Bonneau O; Konstantinova I; Pearce A; Rowlands DJ; Jarai G; Westwick J; MacLean MR; Thomas M
Am J Respir Crit Care Med; 2013 Jan; 187(1):78-89. PubMed ID: 23087024
[TBL] [Abstract][Full Text] [Related]
13. Peptide-coated liposomal fasudil enhances site specific vasodilation in pulmonary arterial hypertension.
Nahar K; Absar S; Gupta N; Kotamraju VR; McMurtry IF; Oka M; Komatsu M; Nozik-Grayck E; Ahsan F
Mol Pharm; 2014 Dec; 11(12):4374-84. PubMed ID: 25333706
[TBL] [Abstract][Full Text] [Related]
14. Temporal hemodynamic and histological progression in Sugen5416/hypoxia/normoxia-exposed pulmonary arterial hypertensive rats.
Toba M; Alzoubi A; O'Neill KD; Gairhe S; Matsumoto Y; Oshima K; Abe K; Oka M; McMurtry IF
Am J Physiol Heart Circ Physiol; 2014 Jan; 306(2):H243-50. PubMed ID: 24240870
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity in lung (18)FDG uptake in pulmonary arterial hypertension: potential of dynamic (18)FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments.
Zhao L; Ashek A; Wang L; Fang W; Dabral S; Dubois O; Cupitt J; Pullamsetti SS; Cotroneo E; Jones H; Tomasi G; Nguyen QD; Aboagye EO; El-Bahrawy MA; Barnes G; Howard LS; Gibbs JS; Gsell W; He JG; Wilkins MR
Circulation; 2013 Sep; 128(11):1214-24. PubMed ID: 23900048
[TBL] [Abstract][Full Text] [Related]
16. [Treatment with imatinib for refractory PAH].
Nakamura K; Akagi S; Sarashina T; Ogawa A; Matsubara H; Ito H
Nihon Yakurigaku Zasshi; 2014 Apr; 143(4):173-7. PubMed ID: 24717604
[No Abstract] [Full Text] [Related]
17. A lymphocyte-dependent mode of action for imatinib mesylate in experimental pulmonary hypertension.
Ormiston ML; Deng Y; Rundle N; Bendjelloul F; Tsoporis JN; Parker TG; Stewart DJ; Courtman DW
Am J Pathol; 2013 May; 182(5):1541-51. PubMed ID: 23518411
[TBL] [Abstract][Full Text] [Related]
18. Synergistic therapeutic effects of 2-methoxyestradiol with either sildenafil or bosentan on amelioration of monocrotaline-induced pulmonary hypertension and vascular remodeling.
Tofovic SP; Jones TJ; Bilan VP; Jackson EK; Petrusevska G
J Cardiovasc Pharmacol; 2010 Nov; 56(5):475-83. PubMed ID: 20881615
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension.
Chhina MK; Nargues W; Grant GM; Nathan SD
Future Cardiol; 2010 Jan; 6(1):19-35. PubMed ID: 20014985
[TBL] [Abstract][Full Text] [Related]
20. Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension.
Gupta V; Gupta N; Shaik IH; Mehvar R; McMurtry IF; Oka M; Nozik-Grayck E; Komatsu M; Ahsan F
J Control Release; 2013 Apr; 167(2):189-99. PubMed ID: 23353807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
